Atnm julyconference

Actinium Pharmaceuticals, Inc.
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium
Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.
No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.
July 2014
Company Presentation
Ticker: ATNM
(NYSE MKT)

2
Disclaimer and Safe Harbor Statement
Disclaimer
The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been approved
by an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation and its slides
for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any
securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in
connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in
these slides or presentation and/or opinions therein. These slides and the presentation are exempt from the general restriction (in section 21 of the
Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have
professional experience in matters relating to investments who fall within Article 19(1) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the “Order”); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling
within Article 49(1) of the Order (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should
not rely on this presentation or any of its contents and all persons (whether relevant persons or otherwise) are recommended to seek their own
independent financial advice from a person authorized for the purposes of the Act before engaging in any investment activity involving the
Company’s securities.
Safe Harbor Statement
This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation
reform act of 1995. Such forward-looking information and statements are based on the current estimates and projections of the Company or
assumptions based on information currently available to the Company. Such statements involve known and unknown risks, uncertainties and other
factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including
changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the
Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s
products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are
reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-
looking information contained in this presentation. Any forward-looking statements or information in this presentation speak only as at the date of
this presentation.

3
Company Description
ACTINIUM is an oncology focused company with proprietary
alpha and beta emitter (radiation) technology initially targeting
early and late stage leukemia. We are one of only three companies
in the world developing alpha emitters.

4
Company Overview
♦ Overall investment of $100M to develop Alpha Emitter
Technology to treat Leukemia
♦ 35 Patents (owned and in-licensed from Memorial Sloan-
Kettering Cancer Center and others)
♦ Advisory Board Represents all Major Cancer Centers
including Memorial Sloan-Kettering, Fred Hutchinson and
MD Anderson
♦ Iomab-B on the cusp of entering Phase III for Relapsed
and Refractory Acute Myeloid Leukemia (AML) (Patients
> 55)

5
Company Overview (continued)
♦ Actimab-A in Phase I/II Trials for Newly Diagnosed AML
♦ 1 of only 3 Companies in World with Alpha Technology
♦ Fully Funded through Late 2015
♦ World Class Board of Directors
♦ Sloan-Kettering Largest Shareholder and also Merck a
Shareholder

6
Financial Facts
Actinium Pharmaceuticals
Stock Ticker ATNM
Stock Exchange NYSE MKT
Market Cap 188.4M
Average 3 Month Volume 134,406
Shares Outstanding 27.4M (40.0M fully diluted)
Float 21.1M
Cash as of Mar 31, 2014 5.9M
Cash from Financing 13.7M

7
Cancer Treatment Options
Treatment % 50% <10%
Pharmaceutical
Revenue %
<3% ~30%
Always a pharmaceutical
Strong IP protection
Mostly proprietary
Monoclonal Antibodies (mAbs)Radiation
External radiation majority treatment
Internal radiation has mostly no IP
Commoditized
♦
♦
♦
♦
♦
♦
Antibody Approaches Targeting Cancer Cells
α
Cancer cell
β
Range
.06mm
Range
1 - 10mm
DNA

8
ATNM’s Proprietary Technology Platform
♦ Delivers radiation to cancer site via pharmaceutical carrier through an injection
– Antibody provides precision, targeting cancer cells specifically while avoiding normal cells
– α emitters provide killing power with a very short range for narrow targeting
– β emitters kill by crossfire which is useful in select indications
* APIT is Actinium Pharmaceutical’s Alpha Particle Immunotherapy platform technology. It does not apply to Iomab-B.
** Certain β emitters, specifically iodine 131 in Iomab-B, do not require a linker.
APIT* Technology
Antibody (targeting agent)
Chelator (linker)
α / β** emitter (killing agent)

9
Clinically Relevant  Emitters
* Clinically relevant but commercially not feasible in ATNM’s opinion.
* * Acquired by Bayer for this amount.
α emitter
Platform
Potential
Half Life Stage IP Ownership
Market Cap
($mm)
Actinium 225 Yes 10 days Phase I/II Actinium Pharmaceuticals
Bismuth 213 Yes 46 minutes Phase II Actinium Pharmaceuticals
Radium 223 No 11 days Marketed Algeta
Thorium 227 Yes 18 days Preclinical Algeta
Astatine 211 * Yes 7 hours Phase II Duke University NM
Lead 212 * Yes 11 hours Phase I Areva Med NM
Bismuth 212 * Yes 1 hour Preclinical NM NM
$141
$1,601
$ 188
$2,900**

10
Robust Intellectual Property Protection
* DOTA is the name of the chelator (linker) that Actinium uses to attach the antibody to the α emitter.
Area Description US Expiration US Status Owner/Licensor
Platform Technology Metastases larger than 1 mm 2019 Issued MSKCC
Platform Technology Antibody conjugates with DOTA chelators;
methods of treating cancer using the same
2021 Issued MSKCC
Drug preparation methods Actinium 225 labeling method 2030 Pending Owned
Drug preparation methods Bismuth 213 labeling method 2019 Issued MSKCC
Isotope production methods Actinium 225 manufacturing in a cyclotron 2026/2027 Issued Owned
Monoclonal antibody composition and production Manufacturing of leukemia targeting antibody 2014 Issued Abbott Laboratories

11
ATNM’s Product Pipeline
s.d. – single dose
f.d. – fractionated dose (2)
1 HSCT stands for Hematopoietic Stem Cell Transplantation, a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.
2 ATNM has decided to discontinue development of Bismab-A at this time due to supply, logistics and cost reasons. Actimab-A is the second generation drug of Bismab-A.
3 Properties of actinium 225 are uniquely suited for Antiangiogenesis and ATNM is considering options for further development in that area.
4 Glioblastoma (GBM) and breast cancer models are founded on an antiangiogenesis approach. Antiangiogenesis therapies starve cancerous tumors by choking off blood supplies to them.

12
Iomab-B: Next Step – Phase III Trial
♦ Experience with 250+ patients in 5 Phase I and II clinical trials
♦ In-licensed from Fred Hutchinson Cancer Center, 7 ongoing physician trials with BC8 mAb
♦ Indication is to condition bone marrow in relapsed and refractory AML patients over 55 years old
in preparation for HSCT
Iomab-B regimen Conventional Care
(high dose chemo followed by HSCT)
♦ Almost all patients eligible ♦ <10% eligible
♦ ~30% survive 1 year plus,
~20% survive 2 years plus
♦ <10% survive 1 year plus,
<2% survive 2 years plus
♦ Up to $200K per patient ♦ Up to $330K per patient
Treatment Options for Older Refractory AML Patients*
Survival:
Cost:
Treatment:
Usage:
*Source: Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):1916-
1924. doi:10.3324/haematol.2012.066100
“Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease”, Dalia Mahmoud, MBA,
Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting abstract.

13
Iomab-B Phase I/II Results
♦ Only potential cure for blood cancers is HSCT, but vast majority of patients over 50 are ineligible
– Iomab-B has demonstrated ability to successfully prepare these patients for HSCT
♦ Clinical trials completed in 250+ patients with various incurable blood cancers
– In both PI and PII trials, Iomab-B led to effective treatment in patients with no other options left
All relapsed/refractory AML patients over 50 Rel/ref AML patients over 50 w/ poor cytogenetics
30%
19%
10%
0%
10%
0%
0%
5%
10%
15%
20%
25%
30%
35%
1 year 2 years
PercentageSurvival
Iomab-B HSCT (N=27)
Current HSCT (N=10)
Chemotherapy (N=61)
33%
16%
3%
0%
3%
0%
0%
5%
10%
15%
20%
25%
30%
35%
1 year 2 years
PercentageSurvival
Iomab-B HSCT (N=18)
Current HSCT (N=19)
Chemotherapy (N=95)
N = Number of patients treated;
Iomab-B results from FHCRC clinical trials;
Current HSCT and Chemotherapy results from MD Anderson outcomes analysis.

14
Iomab-B FDA Meeting Results
♦ A successful End of Phase II meeting was held with the FDA and
agreements were reached on the following
– Path to approval
– Number of studies
– Phase III trial design to support a BLA submission
– Patient population
– Study size (n)
– Primary and secondary endpoints
– Statistical considerations

15
Currently no approved treatments for Iomab-B targeted patients
Phase I and Phase II represent physician trials at Fred Hutchison Cancer Research Center. Phase III trials represent ATNM sponsorship.
Non-AML timelines are projections and the Company makes no representation as to their ability to meet these timelines.
Sources: “Current Uses and Outcomes of Hematopoetic Stem Cell Transplantation 2010”, CIMBTR Summary Slides;
“Trade, foreign policy, diplomacy and health: Pharmaceutical Industry”, WHO website, http://www.who.int/trade/glossry/story073/en/ ;
“Hematopoetic stem cell transplantation A Global Perspective”, NIH Public Access, JAMA 2010; Company Estimates
Iomab-B Development Plan
Indication* 2014 2015 2016 2017 2018 2019 2020 2021 2022
WW Mkt.
potential
Acute Myeloid Leukemia $ 793
Myelodysplastic Syndrome $ 264
Acute Lymphoblastic
Leukemia
$ 264
Non-Hodgkins Lymphoma
and Hodgkins disease
$ 1,455
Multiple Myeloma $ 1,322
Total $ 4,098
III Sales start
III Sales startIII
Sales startII III
III Sales startII
Approval
Approval
Approval
III Sales startIII Approval
Approval

16
Actimab-A vs. Current Treatments
Treatment:
Usage: ♦ 64% of patients 60+ use this
option due to lack of tolerable
alternatives
♦ 36% of patients 60+ are
eligible
♦ Potentially any AML patient
due to limited side effects
Survival: ♦ Less than 2 months ♦ Less than 6 months ♦ Limited history; Bismab-A
trials show median survival is
4x greater
Cost: ♦ $55K per patient ♦ $170K per patient ♦ $60K per patient
New Treatment Option
Supportive Care Actimab-AHigh Dose Chemotherapy
Current Treatment Options*
*Source: ARCH INTERN MED/Vol 162, July 22, 2002;
Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease, Dalia Mahmoud,
MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting.

17
Target: ♦ AML ♦ AML
Effectiveness: ♦ Proof of concept in humans + 500x more potent than Bismab-A
Clinical Stage: ♦ Excellent results in Phase II ♦ Currently in a Phase I/II Trial
Supply Chain: ♦ Complex, high COGS + Simple, 10x lower COGS
Ease of Use: ♦ Complex on site preparation + Central manufacturing
♦ Does not require additional diagnostics ♦ Does not require additional diagnostics
Bismab-A Actimab-A
Actimab-A shows superior efficacy to Bismab-A in a comparable trial
* More than 5% of bone marrow blasts signifies persistent presence of leukemia cells.
Bismab-A Profile Actimab-A Advantages
1st Generation 2nd GenerationAPIT
Platform
Bismab-A experience implies successful Actimab-A trial results
Parameter Bismab-A Actimab-A
Elimination of peripheral blasts 27% 63%
Bone Marrow blasts decrease by 50% or more 28% 50%
Bone Marrow blasts 5% or less post treatment* 0% 20%

18
Actimab-A Clinical Trial Update
♦ Started the new multicenter Phase I/II clinical trial
♦ Expanded the number of participating clinical centers:
– Memorial Sloan-Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer
Center, University of Pennsylvania Health Center, MD Anderson Cancer Center
♦ New protocol sets lower standard than MSKCC PI Trial
– Treating newly diagnosed patients
– Introducing cytoreduction (reduces the number of cancer cells)
– New patient population is likely to respond better to treatment based on medically accepted criteria
– No toxicity outside of blood cells at doses expected to be clinically effective
♦ Targeting end of Phase II trial in 2015, preliminary data by ASH 2014
♦ No new AML drugs have been approved; unmet medical needs remain, which should
create interest from potential licensors, investors (Stemline, Marshall Edwards)

19
Market Positioning for Iomab-B, Actimab-A
Treatment Response TreatmentsDiagnosis
AML
Age >55
Complete
Response
Relapsed &
Refractory
AML
HSCT
Death
High dose
chemotherapy
Actimab-A
Complete
Response
Death
Reduced Intensity
BM Conditioning
Reduced Intensity
BM Conditioning
Iomab-B
♦ HSCT is a procedure
that restores stem cells
destroyed by high doses
of chemotherapy and/or
radiation therapy
♦ HSCT is widely used in
other forms of cancer
outside of AML
♦ ATNM can leverage its
proprietary platform for
additional HSCT
indications
Negative Response
ATNM Pipeline Drugs
Positive Response
Current Treatments
ATNM products target both treatment stages for AML patients over 55 years of age

20
Market Potential of Product Pipeline
♦ The $1.3 billion Bone Marrow Transplant (BMT) market in
the US is largely unaddressed by novel pharmaceutical drug
companies
♦ BMT is the fastest growing hospital procedure in the US
– ~20,000 of the ~60,000 BMTs in 2010 were
performed in the US
♦ Sustained growth in patients treated over 55 yrs old
– 8% in 2000 to 21% in 2005 and 27% in 2007
♦ Acute Myeloid Leukemia is the deadliest form of
leukemia
– 55% of AML patients are over 65 years old
– Disease is worse in older people
– Insufficient treatment options are available in the
marketplace
– Treatment kills as many patients as it helps due to
toxicity
HSCT (Iomab-B) AML (Actimab-A)
1. Target market includes USA, EU and Japan
2. Market Potential calculated based on assumption that Actinium products for solid cancer indications will be priced at $20,000 per treatment;
HSCT preparation product will be priced at $85,000 per treatment; AML product will be priced at $60,000 per treatment; and GBM product
will be priced at $60,000 per treatment. Estimates based on independent third party research and adjusted for lower pricing in non-US
markets.
# Cancer Indication Cases/Yr. in
target market1
Target
Population
Worldwide Market
Potential ($mm)2
1st
HSCT (Bone Marrow) 48,000 48,000 $4,100
2nd
Acute Myeloid Leukemia (AML) 41,600 24,000 $920
3rd
Glioblastoma Multiforme (GBM) 26,500 26,500 $1,100
4th
Prostate Cancer (metastatic) 591,000 298,455 $5,959
5th
Metastatic Colorectal Cancer 536,000 241,200 $4,824
Source: GLOBOCAN, SEER , and the Company

21
Recent Phase I/Phase II Cancer Licensing Deals
Company
Phase at
Signing
Deal
Size
Upfront
Fee Date Deal Description
Algeta Phase II $800 $61 9/3/2009 Algeta signs $800 million deal with Bayer for
Alpharadin in prostate cancer bone metastases
Areva Med Phase I NA NA 7/27/2012 Areva Med signs agreement with Roche for an
alpha radio-immunotherapy platform (Lead-
212) in malignant cancer
Endocyte Phase II $1,000 $120 4/16/2012 Endocyte signs agreement with Merck for
Vintafolide (EC145)
Genmab Phase I/II $1,100 $55 8/30/2012 Genmab signs agreement with Johnson & Johnson
for Daratumumab in multiple myeloma
Innate Pharma Phase I $465 $35 7/6/2011 Innate Pharma signs agreement with Bristol-Myers
Squibb for AML antibody IPH2102
Medivation Phase II $765 $110 10/27/2009 Medivation signs agreement with Astellas Pharma
for MDV3100
Threshold Pharmaceuticals Phase II $592 $25 2/3/2012 Threshold Pharmaceuticals signs agreement with
Merck KGaA for TH-302 in AML and other
indications
Topotarget Phase II $350 $30 2/2/2010 TopoTarget signs agreement with Spectrum
Pharmaceuticals for Belinostat
All Figures in USD ($mm)
Rich deals available for novel technologies with proof of concept
Source: Medtrack, Company Reports.

22
Near-term Value Drivers
♦ Iomab-B
– Complete PIII Protocol
– Start cGMP mAb mfg
– Start drug mfg cGMP process
– Complete cGMP mAb mfg
– Complete Drug mfg cGMP
– Submit PIII IND
– Start PIII
♦ Actimab-A
– Complete PI trial
– Complete mfg. improvements
– Start and complete PII trial
♦ Third Program
– Start preclinical development
– Complete preclinical development
– File IND
Multiple development milestones in next 12-18 months as ATNM’s products advance
to a stage of development
 Uplisting to NYSE MKT
(Accomplished March 26, 2014)
♦ Additional Analyst Coverage
♦ Collaborations

23
Core Team & Advisors
Team Background
Kaushik J. Dave, PhD, MBA
President and CEO,
♦ 25 years of Pharma and Biotech industry at both big Pharma and small startups.
♦ Formerly, EVP at Antares Pharma Inc., VP at Palatin Technologies Inc., and Big Pharma (Schering-Plough and Merck)
♦ BPharm from University of Bath (UK), PhD from University of Kansas, MBA from Wharton School at The University of
Pennsylvania;
Gerri Henwood
Chief Development Officer
♦ President & Founder of Malvern Consulting Group and President & CEO of Recro Pharma
♦ Former Founder, President & CEO of Auxilium Pharmaceuticals, Inc (NASDAQ:AUXL)
♦ Former Founder & CEO of IBAH (formerly NASDAQ listed; acquired by Omnicare (NYSE))
♦ Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc., LZ Therapeutics, Inc., and MAP
Pharmaceuticals, Inc.(NASDAQ:MAPP)
Dragan Cicic, MD, MBA
COO & CMO
♦ 9 years at Actinium Pharmaceuticals (ATNM), previously serving as Medical Director
♦ Formerly a strategic consultant at QED Technologies and an investment banker at SG Cowen Securities
♦ MBA, Wharton School at The University of Pennsylvania; MD, School of Medicine at The Belgrade University
♦ Nieman Fellow at Harvard University
Richard Steinhart BBA, MBA
Director
♦ Industry Consultant
♦ Formerly Senior Vice President, Finance and Chief Financial Officer of MELA Sciences Inc.
♦ Formerly Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and
management consulting firm focused on healthcare and technology companies.
♦ B.B.A. and M.B.A., Pace University
Sergio Traversa, PharmD, MBA
Director
♦ CEO of Relmada Therapeutics, Inc.
♦ 25+ years of management and investment experience in healthcare as a Portfolio Manager & Sr. Pharmaceutical Analyst (Mehta &
Isaly, ING Barings, Merlin BioMed & Rx Capital) and in industry (CNS at Eli Lilly, Pfizer)
♦ MBA, Finance at New York University, Laurea of Pharmacy at the University of Turin
David Nicholson, PhD
Director
♦ Head of R&D, Bayer CropScience
♦ Formerly Sr. VP and Head Worldwide Licensing and Knowledge Management at Merck
♦ Formerly Head of R&D at Organon prior to acquisition by Schering-Plough
♦ Ph.D., University of Wales
Sandesh Seth, MS, MBA
Chairman of the Board
♦ Head of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd.
♦ 20+ years experience in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in
industry (Pfizer, Warner-Lambert, SmithKline)
♦ MBA, Finance at New York University; MS, Pharmaceutical Sciences at University of Oklahoma Health Center

24
Clinical Advisory Board
Treatment Center Advisory Board Members
Memorial Sloan Kettering
Cancer Center
David Scheinberg, M.D., PhD
Chairman of Experimental Therapeutics at MSKCC
Vincent Astor Chair
Scientific Co-Founder
Fred Hutchinson
Cancer Center
Elihu H. Estey, M.D.
Professor of Medicine
Division of Hematology
University of Washington School of Medicine
WHO Treatment guidelines for AML
John Pagel, M.D., PhD
Assistant Professor/Assistant Member
Department of Medicine, Division of Oncology
Lead Investigator for Iomab-B
MD Anderson Cancer Center Hagop Kantarjian, M.D.
Professor of Leukemia
Department Chair, Department of Leukemia
Division of Cancer Medicine
University of Texas
Key Investigator for Actimab-A
Johns Hopkins Medicine Richard Wahl, M.D.
Director, Division of Nuclear Medicine/PET
Professor of Nuclear Medicine
Professor of Radiology and Oncology
Vice Chairman, Technology and New Business Development
Department of Radiology
“Father of PET Imaging”
Judith Karp, M.D.
Professor of Oncology
Director, Adult Leukemia Program, Division of
Hematologic Malignancies
The Sidney Kimmel Comprehensive Cancer Center
Columbia University
Medical Center
Joseph G. Jurcic, M.D.
Professor of Clinical Medicine
Director of Hematologic Malignancies
Hematology/Oncology Division
CAB Chairman, Lead Investigator for Actimab-A trials
University of Pennsylvania
Health System
Alexander Perl, M.D.
Assistant Professor of Medicine
Division of Hematology/Oncology

25
Highlights
 Prior clinical data for both Iomab-B and Actimab-A favor successful
trial results
 Breakthrough therapy potential implies successful market penetration
for both Iomab-B and Actimab-A
 APIT platform poised to deliver multiple blockbuster cancer drugs
 An expert team possessing the vision and desire to enhance
shareholder value
 Positioned to benefit from increased market recognition of targeted
payload therapies and an initial high-value, niche product model

Atnm julyconference

Recommandé

Recommandé

Contenu connexe

En vedette

En vedette (14)

Similaire à Atnm julyconference

Similaire à Atnm julyconference (20)

Plus de RedChip Companies, Inc.

Plus de RedChip Companies, Inc. (20)

Atnm julyconference